Drug
Oralgen
Oralgen is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
25%
Ph phase_4
1
25%
Ph phase_2
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (50.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
Trials by Status
completed375%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Long-term Efficacy and Safety Study With Oralgen Grass Pollen
NCT00824447
completedphase_2
Efficacy and Safety of Grass Pollen Sublingual Immunotherapy
NCT00567346
unknownphase_3
A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis
NCT00812799
completedphase_4
Effects of Sublingual Immunotherapy on Grasspollen Allergy
NCT00150514
Clinical Trials (4)
Showing 4 of 4 trials
NCT00824447Phase 2
Long-term Efficacy and Safety Study With Oralgen Grass Pollen
NCT00567346Phase 2
Efficacy and Safety of Grass Pollen Sublingual Immunotherapy
NCT00812799Phase 3
A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis
NCT00150514Phase 4
Effects of Sublingual Immunotherapy on Grasspollen Allergy
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4